Pepper Bio, a VSC Ventures portfolio company, went out of business as of September 24, 2026.
SEP 24, 2026
Pepper Bio develops a transomics platform for drug discovery that integrates phosphoproteomic, genomic, transcriptomic, and proteomic data to reveal disease biology, identify therapeutic targets, stratify patients, and predict drug response and efficacy
Pepper Bio develops a transomics platform for drug discovery that integrates phosphoproteomic, genomic, transcriptomic, and proteomic data to reveal disease biology, identify therapeutic targets, stratify patients, and predict drug response and efficacy. It partners with pharmaceutical and biotech R&D teams, with applications across oncology, neurology, and inflammatory diseases.